Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
- Conditions
- HemangiomaInfant
- Interventions
- Drug: Control (placebo) group
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 6
- Registration Number
- NCT01147601
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 643
- Registration Number
- NCT01026831
A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 160
- Registration Number
- NCT00991822
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Interaction Study of Timolol Eye Drops and Paroxetine Capsules
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 12
- Registration Number
- NCT00879099
- Locations
- 🇫🇮
University of Helsinki, Department of Clinical Pharmacology, Helsinki, Biomedicum, Finland
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
- Conditions
- Open-angle GlaucomaOcular HypertensionGlaucoma
- Interventions
- Drug: i. Fixed combination of latanoprost 0.005% and timolol 0.5%
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 436
- Registration Number
- NCT00856622
- Locations
- 🇩🇪
Pfizer Investigational Site, Weiden, Germany
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Vistakon Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT00823043
- Locations
- 🇺🇸
Eye Care of San Diego, San Diego, California, United States
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionGlaucoma, Open Angle
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Vistakon Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00804648
Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema
- Conditions
- Corneal EdemaVisual Acuity
- Interventions
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2008-12-02
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT00800423
- Locations
- 🇮🇱
Rabin medical center ophthalmology deparment, Petah-Tikva, Israel
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 418
- Registration Number
- NCT00800267
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 111
- Registration Number
- NCT00763061
- Locations
- 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.